Trofinetide

Peptide

Approved / Phase 4Mechanism not established
Approvedregulatory verdict

Evidence outlook

Approved: Rett Syndrome

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (2)
EU
  • Treatment of neurobehavioural symptoms of Rett syndrome in patients aged 5 years and older (brand DAYBU)
Product first approved 2026EMA
CA
  • Treatment of Rett syndrome in adult and pediatric patients two years of age and older
Product first approved 2024acadia.com

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (3)
Rett Syndrome
NCT04776746 · ACADIA Pharmaceuticals Inc.
2020-11-08 – 2023-06-30 · Rett Syndrome
What this study did
Phase 2/3 (1)
Rett Syndrome
NCT04988867 · ACADIA Pharmaceuticals Inc.
2021-09-22 – 2023-05-31 · Rett Syndrome
What this study did
Phase 2 (6)
Rett Syndrome
NCT02715115 · Neuren Pharmaceuticals Limited
2016-03 – 2017-01-05 · Rett Syndrome
What this study did
NCT01703533 · Neuren Pharmaceuticals Limited
2013-03 – 2014-09 · Rett Syndrome
What this study did
Other / comorbidity
NCT02100150 · Neuren Pharmaceuticals Limited
2014-09 – 2016-06 · Concussion
What this study did
NCT01366820 · Neuren Pharmaceuticals Limited
2013-02 – 2016-01 · Brain Injuries
What this study did
NCT00805818 · Neuren Pharmaceuticals Limited
2010-04 – 2016-01 · Brain Injuries
What this study did
NCT01894958 · Neuren Pharmaceuticals Limited
2014-01 – 2015-10 · Fragile X Syndrome
What this study did
Phase 1 (2)
Other / comorbidity
NCT01420042 · Neuren Pharmaceuticals Limited
2012-02 – 2012-09 · Brain Injuries, Traumatic
What this study did
NCT00961779 · Neuren Pharmaceuticals Limited
2010-03 – 2010-09 · Brain Injuries, Traumatic
What this study did
Early phase / not applicable (1)
Rett Syndrome
NCT07730112 · Colorado State University
2026-08-01 – 2028-05-31 · Rett Syndrome, Family Caregivers, Social Support, Psychological Support
What this study did

Competitive landscape

This drug's own stage for Rett Syndrome: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Trofinetide: this drugApprovedPeptide—Reliable signalNo reviewed efficacy summary in this indication
Fenfluramine (Fintepla)Phase 3Small moleculeSerotonin 5-HT2 receptorsnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Trofinetide to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
May 2028 (1)
Early phase / not applicableRett SyndromeNot yet recruiting
Est. primary completion 2028-05-31 · NCT07730112 · CT.gov ↗
What to watch

See the full readout calendar ↗